30
Participants
Start Date
December 6, 2011
Primary Completion Date
March 1, 2015
Study Completion Date
October 31, 2017
Capecitabine
1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
Cisplatin
80 mg/m2 on Day 1 of each cycle
Pertuzumab
loading dose of 840 mg, then 420 mg once every three weeks
Pertuzumab
840 mg once every three weeks
Trastuzumab
loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
Cliniques Universitaires St-Luc, Brussels
UZ Leuven Gasthuisberg, Leuven
Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo., Berlin
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milan
Hospital Universitario La Paz; Servicio de Oncologia, Madrid
Hopital Morvan, Brest
CRLCC Val dAurelle Paul Lam, Montpellier
Klinikum Braunschweig; Medizinische Klinik III; Klinik für Hämatologie und Onkologie, Braunschweig
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia
Hopital Robert Debre; DERMATOLOGIE, Reims
A.O. Universitaria Pisana; Oncologia, Pisa
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie, Frankfurt
Klinikum Mannheim III. Medizinische Klinik, Mannheim
Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro
Masaryk Memorial Cancer Institute; Oncological Clinic, Brno
Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Králové
Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc
Fakultní Nemocnice V Motole; Radioterapeuticko-Onkologicke Oddeleni, Prague
University Hospital Na Bulovce; Institut of Radiation Oncology, Prague
Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul
Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology, Seoul
Asan Medical Center; Medical Oncology, Seoul
Hospital del Mar; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY